Endocrinology Search
Endocrinology Endocrinology
obesity
OBESITY
Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.

Diagnosis

History

  • Elicit the following in the history: Weight history, eating habits, physical activity, alcohol consumption, smoking, underlying diseases or conditions that hinder physical activities or weight loss
  • Exclude secondary causes of obesity, such as medications (eg Insulin, Nateglinide, Repaglinide, Risperidone, Sertindole, Olanzapine,
  • Clozapine, Mirtazapine, Valproate, Gabapentin), or history of genetic or endocrine disorders (eg hypothyroidism)
  • Detect potential comorbidities (eg diabetes mellitus (DM), hypertension, dyslipidemia, sleep apnea, hyperinsulinemia)
    • Its presence may affect the treatment decisions and outcomes
  • Assess psychologic mental status (eg patient’s self image, general mental health, stress factors, eating disorder, presence of depression and other mood disorders, substance abuse)
  • Detect pregnancy/lactation in women
    • Not usually recommended for weight loss program
  • Family history (eg obesity, presence of cardiovascular (CV) disease, hypertension, DM, dyslipidemia, obesity-related cancer, thyroid disease)

Physical Examination

  • BP measurements
  • Physical exam for evidence of goiter, Cushing’s syndrome, hypogonadism and dysmorphism

Anthropometry

  • BMI
    • Measures relative weight for height
    • Indicates total body fat content
    • An accurate predictor of future health status, as raised BMI increases CV events or deaths, total mortality, DM, sleep disorder, OA and certain cancers (eg endometrial, breast, colon)
    • Done annually for screening and as needed for management
    • Calculated by the formula: BMI = weight (kg)/[height (m)]2
    • Calculation is for all age group, BMI percentile for age is used in children <18 years old to determine the healthy weight status 
  • Waist Circumference
    • Useful measurement of intra-abdominal fat content before and during weight loss treatment
    • Technique of choice for classifying central obesity and clinical risk
    • A large waist circumference is associated with an increased risk for DM, dyslipidemia, hypertension and CV disease in patients who may not be considered obese by conventional BMI criteria

Laboratory Tests

  • To assess comorbidities associated with obesity
    • Lipid profile [eg low-density lipoprotein cholesterol (LDL-C), HDL-C and triglyceride (TG)]
    • Fasting glucose level, A1C, thyroid function tests
    • Uric acid, liver function (hepatic enzymes), renal function
    • Urine free cortisol levels (perform in patients with signs of Cushing’s syndrome)
    • Lab tests to rule out polycystic ovarian syndrome
    • Electrocardiogram (ECG)
    • Chest X-ray

Assessment

Risk Factor Assessment

Identify absolute risk status based on the presence of the following:

  • Disease Conditions
    • Coronary heart disease (CHD)
    • Atherosclerosis
    • Hypertension
    • DM
    • Sleep apnea
    • Dyslipidemia
  • Other Obesity-Associated Diseases
    • Gynecological disorders (eg menorrhagia, amenorrhea)
    • Osteoarthritis (OA)
    • Asthma
    • Gallstones
    • Stress incontinence
    • Nonalcoholic fatty liver disease
    • Gastroesophageal reflux disease
  • CV Risk Factors
    • Cigarette smoking
    • Hypertension
    • Hyperlipidemia
    • Impaired fasting glucose and impaired glucose tolerance
    • Family history of premature CHD [eg myocardial infarction (MI) or sudden death in father/male 1st-degree relative at ≤55 years or mother/female 1st-degree relative at ≤65 years]
    • Age ≥45 years for men or age ≥55 years for women or postmenopausal
  • Others
    • Physical inactivity
    • Elevated serum TG (>2.3 mmol/L) and decreased HDL-C

Classification

ADULT CLASSIFICATION OF WEIGHT BY BODY MASS INDEX
WHO Classification WHO BMI Cut-off Points (kg/m2) Risk of Comorbidities Asian BMI Cut-off Points (kg/m2)
Underweight <18.5 Low but increased risk of other clinical problems <18.5
Normal 18.5-24.9 Average 18.5-22.9
Overweight ≥25.0   ≥23.0
Pre-obese 25.0-29.9 Increased 23.0-27.4
Obese Class I 30.0-34.9 Moderate 27.5-34.9
Obese Class II 35.0-39.9 Severe 35.0-39.9
Obese Class III ≥40.0 Very severe ≥40.0
Race High-Risk Waist Circumference (cm)
Men Women
Caucasians ≥102 ≥88
Asians ≥90 ≥80
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Obesity negatively influences certain outcomes in rheumatoid arthritis
5 days ago
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
CV Risk and T2D—SGLT2 inhibitors: Redefining the Clinical Management of T2D
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Topical capsaicin as effective as oral agents for pain relief in PDPN
17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.